Indian Pricing Authority Intent On Recovering Funds From Drug Companies That Allegedly Overcharged Consumers
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's drug price regulator, the National Pharmaceutical Pricing Authority, which monitors and fixes drug prices and their availability in India, has accelerated its efforts to recover $411 million that drug manufacturers have allegedly overcharged consumers for controlled drugs in the last 12 years
You may also be interested in...
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
While the need for price control of drugs continues to be a hot topic for debate, Dr A.K. Banerjee, the man carrying the onus of regulating drug prices in India as the chairman of the National Pharmaceuticals Pricing Authority, presents his viewpoint to PharmAsia News' India bureau on the need for price control in the country.
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
While the need for price control of drugs continues to be a hot topic for debate, Dr A.K. Banerjee, the man carrying the onus of regulating drug prices in India as the chairman of the National Pharmaceuticals Pricing Authority, presents his viewpoint to PharmAsia News' India bureau on the need for price control in the country.
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
Over half the population is uninsured, and unlike consumer durables where buying decisions depend on personal research and budget, in medicines their purchase decisions hinge on what is prescribed by doctors not by free choice, Banerjee argues.